• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Kyongbo Pharmaceutical

    Biosynth Carbosynth

    Aphena Pharma Solutions

    IDT Biologika
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Kyongbo Pharmaceutical

    Biosynth Carbosynth

    Aphena Pharma Solutions

    IDT Biologika
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Changing Dynamics: The CDMO market in focus

    Contract Pharma talks with executives about trends in the CDMO market

    Changing Dynamics: The CDMO market in focus
    Related CONTENT
    • WuXi AppTec
    • Altasciences
    • Recipharm
    • Lilly, Sigilon Partner for Diabetes
    • APC Expands Executive Team
    Tim Wright, Editor, Contract Pharma04.10.18
    The drug industry’s desire to tap emerging opportunities, combined with its focus on innovative therapies, is reshaping the contract manufacturing sector.

    Contract development and manufacturing organizations (CDMOs) are investing in new technologies, adding capacity and building in new markets according to Jean-Francois Hilaire, executive vice president and head of strategy and global integration at Recipharm, and Yu Lu, executive director, corporate development and communications, STA Pharmaceutical, a WuXi AppTec company, who shared their thoughts on the changing industry dynamics with Contract Pharma.

    Contract Pharma: How is the pharmaceutical market changing and how is this impacting drug companies?

    Jean-Francois Hilaire, Recipharm: Three key dynamics are driving the growth of the pharmaceutical market. Firstly, regulatory support for ‘breakthrough therapies,’ which are drugs granted priority review because they address actual medical needs. Developers recognize the value of making such medicines available to patients as quickly as possible, and therefore focus their R&D efforts on innovative, high value therapies.

    The second major growth driver is the ageing global population. The increasing elderly population is prompting drug companies to hike production volumes to cater for growing demand.

    Thirdly, new markets are emerging as healthcare standards improve around the world. This is another real opportunity for pharmaceutical companies to supply growing volumes of mature treatments.

    However, while there are these opportunities, taking advantage of them is technically challenging and requires significant R&D investment, capacity and market reach. In addition, there is growing price pressure in the marketplace.

    Yu Lu, STA Pharmaceutical, a Wuxi AppTec company: The major change we see in the market is within the discovery pipeline itself and the resultant effects this is having on the supply chain. New drug development timelines, in particular drugs targeting oncology, have been shortened than ever before. Molecules coming into development are more complex and more newer modalities beyond traditional small molecules and biologics emerge such as Antibody Drug Conjugates (ADCs), peptides, oligonucleotides, and various combination of conjugates. The other major change we observed is that five years ago most of STA’s business would come from the U.S. and Europe. But increasingly we are seeing more and more companies from other regions such as China, Japan and Canada developing new drugs for global markets. In particular in China this trend is now being accelerated by various recent regulatory reforms, which is not only fostering the growth of domestic biotechs in the country, but is also encouraging more foreign drug license holders to enter too.

    CP: And how is this impacting the contract services sector?
    Jean-Francois Hilaire:
    It depends on the type of product. For drugs that are technically challenging to develop and manufacture like biologics, some companies are starting to outsource production to access external expertise, technology or capacity unavailable in-house. This is a positive trend for CDMOs with the capabilities to take on such projects.

    For generics, it is all about volume production at controlled cost which is also positive for CMOs that can offer such capacity. In addition, the ability to cater for growing demand for mature products in so called ‘pharmerging’ markets also provides CMOs with the opportunity to win contracts.

    Yu Lu: Overall, contract service providers now need to have a far wider scope of development capabilities and larger capacity to deal with the shortened development timeline as well as increased variety and complexity of products entering development. But it is also meaning they have to be increasingly global with customers now coming from a wider spread of geographic regions—and as such they need to be regulated by a greater number of global bodies and familiar with a wide array of regulatory requirements.

    CP: What are the major areas of opportunity for the CDMO sector?
    Jean-Francois Hilaire:
    It is important to recognize that customer expectations are changing. The question is no longer does a CDMO have capacity to make solids or sterile liquids. Instead, customers want CDMOs to form long term strategic partnerships, share expertise and help support product development.

    Customers also want a contractor which can help it reach the market earlier than competitors, which is creating a demand for a full service offering to help manage the complexity of the drug development process. In addition, drug companies seek CDMOs that are reliable during technical transfer and those that can secure process performance improvements along the life cycle of the product.

    Yu Lu: We are now increasing the depth and scope of our collaborations with our customers. Similarly, for the biotechs we work with there is a tremendous assurance in being able to offer such a broad spectrum of capabilities as they rely upon CDMO partners to take their products from inception right through to commercialisation—and the speed at which we can achieve milestones plays a big part in being able to achieve next stage funding.

    CP: What is driving demand for full service CDMOs?
    Jean-Francois Hilaire:
    CDMOs that offer a wide range of services and a global footprint are in demand as they help to simplify the supply chain while also fulfilling the quality level expectations of multiple markets. Increasingly, drug firms aim to reduce their networks to a few suppliers that provide a range of services for a range of product types.

    Likewise, specialty pharma, virtual companies and generic firms, want a range of services, from development and production, through to supply chain support. Melding development services with commercial supply is highly valued due to its ability to ultimately reduce costs and timelines.

    Yu Lu: Undoubtedly, pharma will continue to outsource more of its development and manufacturing capabilities. With this mind, and the growth of biotechs that are in need of outsourcing specialists, the CDMO sector looks well set for continued growth. There is now a real advantage to scale, simply in terms of the number of process R&D scientists and production equipment needed to advance compounds quickly. Speed to clinic has always been a driver for pharmaceuticals, a streamlined full service provider is able to save time by retaining knowledge from early stage to late stage development to commercialization. The lengthy and costly technology transfer process between different CDMOs can also be avoided.

    CP: Why isn’t every CDMO a full-service contractor? Why are there still specialists?
    Jean-Francois Hilaire:
    Production and development of breakthrough therapies and standard products can require significant technical expertise, as well as costly investment in technology. Also, customers are paying greater attention to detail and demanding quality that exceeds the requirements of regulatory agencies.

    As a result, some CDMOs remain as ‘specialists’, focusing on a defined field of competences, such as the development and production of high potency APIs, large molecule production or downstream sterile liquid fill & finish.

    Yu Lu: The most successful contract providers now fall into two broad types of CDMO; ones that offer full service capabilities and a second group of niche providers offering specialist capabilities in certain areas. Only a handful of CDMOs currently have wide enough capabilities to be truly described as full service. But what we anticipate, is that the future will be defined by CDMOs with both full services capabilities and specialist technologies that enable them to develop a full spectrum of complex products coming through the pipeline.

    CP: Finally, the CDMO sector has often been described as ripe for consolidation. Is this still the case?
    Jean-Francois Hilaire:
    Yes. The largest CDMOs hold just 2-4% of the market and the top ten CMOs represent less than 30%. There are many consolidation opportunities still available, and buying expertise remains an attractive prospect for a CDMO with sufficient financial resources. Recipharm’s approach is a good example. Recipharm is recognised as the ‘top consolidator’ with a total of ten acquisitions in markets including Europe, the US and Asia (Consolidation of the CDMO industry—Ernst & Young—September 2017).

    Our merger and acquisition (M&A) strategy is focused on gaining new technical capabilities as well as expanding geographic reach. A good example is our recent acquisition of Kemwell’s pharmaceutical branch in India. This deal gave our customers access to a wider range of services, cost effective development and manufacturing capabilities as well as extended technical expertise.

    Yu Lu: As an industry, the contract services space is still very active in terms of merges and acquisitions—certainly the medium sized CDMOs are seeking scale to compete and the larger players are looking for new technologies that bring a capability advantage. In terms of WuXi STA we are also looking for new opportunities, in particular focusing on special capabilities that fits with our broad platforms in both the USA and China. It’s in part why we have chosen to invest so heavily in our own new commercial and development facilities—so that we can be equipped with the best available technologies rather than relying upon legacy sites and old technologies as many others have done in the past. 
    Related Searches
    • production
    • Outsourcing
    • apptec
    • license
    Suggested For You
    WuXi AppTec WuXi AppTec
    Altasciences Altasciences
    Recipharm Recipharm
    Lilly, Sigilon Partner for Diabetes Lilly, Sigilon Partner for Diabetes
    APC Expands Executive Team APC Expands Executive Team
    Solid Dosage Outsourcing Trends Solid Dosage Outsourcing Trends
    Pharma Year 2017 in Review Pharma Year 2017 in Review
    Retrophin Appoints Corporate Development VP Retrophin Appoints Corporate Development VP
    The Past, Present and Future of Sourcing and Procurement The Past, Present and Future of Sourcing and Procurement
    Leadership Perspective: CDMO/Sponsor Partnerships Leadership Perspective: CDMO/Sponsor Partnerships
    Rimidi, Eli Lilly Enter Partnership for Diabetes Management Rimidi, Eli Lilly Enter Partnership for Diabetes Management
    The Past, Present and Future of Sourcing and Procurement The Past, Present and Future of Sourcing and Procurement
    CEO Spotlight: Sterling Pharma Solutions CEO Spotlight: Sterling Pharma Solutions
    Emerging Partnership Models between Emerging Companies, CDMOs, and Big Pharma Emerging Partnership Models between Emerging Companies, CDMOs, and Big Pharma
    Astellas Appoints RWI VP Astellas Appoints RWI VP

    Related Content

    • WuXi AppTec

      ...
      Daja Herald, Marketing Director 11.22.21

    • Altasciences

      Altasciences

      ...
      Ben Reed, VP, Manufacturing 10.28.19

    • Recipharm

      Recipharm

      ...
      Recipharm AB 10.24.19


    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Laboratory Testing
      Lilly, Sigilon Partner for Diabetes

      Lilly, Sigilon Partner for Diabetes

      The collaboration is to develop encapsulated cell therapies for the potential treatment of type 1 diabetes
      04.04.18

    • Promotions & Moves
      APC Expands Executive Team

      APC Expands Executive Team

      Names David Downey chief commercial officer; Eoin McManus as chief operating officer
      03.20.18

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • LabVantage Solutions Adds Mixed Reality Technology to Its Advanced LIMS Platform
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Dr. Tammo Boinowitz to Join ALTANA's Management Board
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
      Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      DIY Nail Care Is Outperforming the Professional Segment: Kline
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login